JP2009514527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009514527A5 JP2009514527A5 JP2008538857A JP2008538857A JP2009514527A5 JP 2009514527 A5 JP2009514527 A5 JP 2009514527A5 JP 2008538857 A JP2008538857 A JP 2008538857A JP 2008538857 A JP2008538857 A JP 2008538857A JP 2009514527 A5 JP2009514527 A5 JP 2009514527A5
- Authority
- JP
- Japan
- Prior art keywords
- klh
- adjuvant
- immunogenic
- immunostimulatory
- imiquimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/042068 WO2007055704A2 (en) | 2005-11-07 | 2005-11-07 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009514527A JP2009514527A (ja) | 2009-04-09 |
| JP2009514527A5 true JP2009514527A5 (enExample) | 2011-10-06 |
| JP5184366B2 JP5184366B2 (ja) | 2013-04-17 |
Family
ID=38023711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538857A Expired - Fee Related JP5184366B2 (ja) | 2005-11-07 | 2005-11-07 | 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP2371956A3 (enExample) |
| JP (1) | JP5184366B2 (enExample) |
| CN (1) | CN101351228A (enExample) |
| AT (1) | ATE529511T1 (enExample) |
| AU (1) | AU2005338035B2 (enExample) |
| CA (1) | CA2628306C (enExample) |
| MX (1) | MX2008006005A (enExample) |
| WO (1) | WO2007055704A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| JP5737937B2 (ja) * | 2007-07-09 | 2015-06-17 | イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物 |
| JP5563455B2 (ja) * | 2007-08-01 | 2014-07-30 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の新規な合成アゴニスト |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| TW244371B (enExample) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5912332A (en) | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| JP5268214B2 (ja) | 1999-08-13 | 2013-08-21 | イデラ ファーマシューティカルズ インコーポレイテッド | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調 |
| AU783687B2 (en) | 2000-01-26 | 2005-11-24 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| KR101123489B1 (ko) * | 2003-01-16 | 2012-03-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절 |
| US7427405B2 (en) * | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
-
2005
- 2005-11-07 AU AU2005338035A patent/AU2005338035B2/en not_active Ceased
- 2005-11-07 CN CNA2005800524843A patent/CN101351228A/zh active Pending
- 2005-11-07 JP JP2008538857A patent/JP5184366B2/ja not_active Expired - Fee Related
- 2005-11-07 WO PCT/US2005/042068 patent/WO2007055704A2/en not_active Ceased
- 2005-11-07 CA CA2628306A patent/CA2628306C/en not_active Expired - Fee Related
- 2005-11-07 AT AT05851907T patent/ATE529511T1/de not_active IP Right Cessation
- 2005-11-07 MX MX2008006005A patent/MX2008006005A/es active IP Right Grant
- 2005-11-07 EP EP11001257A patent/EP2371956A3/en not_active Withdrawn
- 2005-11-07 EP EP05851907A patent/EP1942945B1/en not_active Expired - Lifetime
- 2005-11-07 EP EP11003299.2A patent/EP2402442B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94900C2 (uk) | Вакцина | |
| DK1959992T3 (da) | Immunogen sammensætning indeholdende en adjuvans. | |
| ATE276758T1 (de) | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid | |
| WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| WO2007095976A3 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| JP2009514527A5 (enExample) | ||
| MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
| WO2009010877A3 (en) | Conjugate purification | |
| DK1898948T3 (da) | Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans | |
| ATE383872T1 (de) | Ein immunostimulierendes nukleotid und ein tocol enthaltende zusammensetzung | |
| NZ585674A (en) | Vaccination with multiple clades of h5 influenza a virus | |
| CU23810A3 (es) | Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico | |
| AU2457100A (en) | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs | |
| WO2006113372A3 (en) | Porcine circovirus and helicobacter combination vaccines | |
| CA2763359C (en) | New human rotavirus strains and vaccines | |
| JP2009514525A5 (enExample) | ||
| RU2006138283A (ru) | Поливалентная вакцина для иммунотерапии рака на основе mage-3 и ny-eso-1 | |
| WO2008056174A3 (en) | Novel compositions and uses thereof | |
| EP1829887A4 (en) | CPG single-stranded desoxynucleotides for use as ADJUVANS | |
| FR2922767B1 (fr) | Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant. | |
| WO2007006712A3 (en) | Mycoplasma subunit vaccine | |
| CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
| WO2006136460A8 (en) | New adjuvant | |
| GB2444676A (en) | Adjuvanted vaccine |